To reveal specific mechanisms of drug resistance about bevacizumab treatment in GBM patients who have prolonged disease free survival (DFS), but retained overall survival (OV), we established systemic drug-resistance murine GBM model in the context of tumor evolutionary with time series brain tissue collection. And to trace the change of specific functional molecules along the bevacizumab resistance, we performed LC-MS/MS-based global, phospho-proteomic analysis and NGS-based transcriptomic analysis using the time series murine GBM model.